Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Nordic Nanovector ASA ( (DE:8NN) ) is now available.
Thor Medical ASA announced the conclusion of its subscription period for a subsequent offering of up to 4,000,000 new shares at NOK 2.50 per share, ending on 3 July 2025. This offering is part of the company’s strategy to enhance its capital structure, potentially impacting its market position and stakeholder interests by providing additional financial resources for growth and development.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier in the radiopharmaceutical industry, focusing on the provision of radionuclides, particularly alpha particle emitters derived from naturally occurring thorium. The company utilizes a proprietary production process that is environmentally friendly and cost-efficient, avoiding the need for irradiation or nuclear reactors. Thor Medical is based in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
Average Trading Volume: 2,192,367
Current Market Cap: NOK793.9M
Find detailed analytics on 8NN stock on TipRanks’ Stock Analysis page.